For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | |
|---|---|---|---|---|
| General and administrative | 1,136,709 | 328,510* | 1,754,856 | |
| Research and development | 109,434 | -210,527* | 158,699 | |
| Total operating expenses | 1,246,143 | 117,983 | 1,913,555 | |
| Loss from operations | -1,246,143 | -117,983* | -1,913,555 | |
| Net gain from change in fair value of derivative liability instrument | 697,561 | 2,487,591.5* | - | |
| Gain from change in fair value of forward contract liability | - | -95,110.5* | - | |
| Amortization of deferred offering cost | 477,647 | 124,237* | - | |
| Interest income | 49,679 | 14,250* | 5,111 | |
| Other income | 5,578 | 163,740* | 4,260 | |
| Total other income | 275,171 | 2,636,455* | 9,371 | |
| Net gain | -970,972 | 2,518,472 | -1,904,184 | |
| Basic EPS | -0.03 | 0.092 | -0.07 | |
| Diluted EPS | -0.03 | 0.092 | -0.07 | |
| Basic Average Shares | 29,476,002 | 27,456,883 | 27,975,207 | |
| Diluted Average Shares | 29,476,002 | 27,456,883 | 27,975,207 | |
Turn Therapeutics Inc. (TTRX)
Turn Therapeutics Inc. (TTRX)